On February 25, 2026 Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, reported that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company’s strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Fireside Chat and Q&A session will be webcast live during the conference on the company’s investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until March 25, 2026.

(Press release, Quest Diagnostics, FEB 25, 2026, View Source [SID1234662993])

On February 25, 2026 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, reported that Robert Lyne, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. A webcast of the presentation will be available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, PureTech Health, FEB 25, 2026, View Source [SID1234662992])

On February 25, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported its unaudited financial results for the fourth quarter of 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financial report and corresponding presentation are attached hereto and can also be accessed in the Investors section of the company’s website: View Source

The company will host a webcast presentation at 3 p.m. CET / 9 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: View Source;tp_key=fc0d227753

(Press release, Nykode Therapeutics, FEB 25, 2026, View Source [SID1234662991])

On February 25, 2026 Novabridge Biosciences presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, NovaBridge Biosciences, FEB 25, 2026, View Source [SID1234662990])

On February 25, 2026 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, reported that Company management will participate in these upcoming conferences in March:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s Health Care Conference
Date: Wednesday, March 4, 2026
Location: Boston, MA
Time of the fireside chat: 11:10am ET / 5:10pm CET
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

UBS Biotech Summit Miami
Date: Monday, March 9, 2026
Location: Miami Beach, FL

Jefferies Biotech on the Beach Summit
Date: Tuesday, March 10, 2026
Location: Miami Beach, FL

Leerink’s Global Healthcare Conference
Date: Wednesday, March 11, 2026
Location: Miami Beach, FL
Time of the fireside chat: 2:20pm EDT / 7:20pm CET
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

(Press release, Nanobiotix, FEB 25, 2026, View Source [SID1234662989])